Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium ion (clotting factor IV) is not a protein or traditional receptor, but rather an essential cofactor orchestrating multiple steps in the coagulation cascade. Ca2+ enables gamma-carboxylated coagulation factors (e.g., factors II, VII, IX, X) and membrane surfaces (phosphatidylserine on activated platelets) to bind each other, localize to damaged vasculature, and form the protein complexes necessary for progressive thrombin generation and fibrin formation. Without Ca2+, secondary hemostasis fails and stable clot formation is impossible. To summarize, "clotting promotion via Ca2+" is not a precise drug target, but a description of calcium’s biochemical necessity in normal and abnormal coagulation. The only direct clinical interventions relate to calcium’s removal (anticoagulation of blood samples, transfusion protocols) or supportive management of calcium balance, not to drugs selectively targeting a “receptor” or molecular target in the classic sense.
Chelators stop clotting by binding free Ca2+ and preventing its biological function in the cascade
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calcium ion (clotting factor IV) (Ca2+).